Name: AMGN Debt Components
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#dissemination

Amgen Inc. (AMGN) Debt Components

2026-06-30: Commercial PaperUSD (m); Long-term Debt, Current MaturitiesUSD $5.45B; Long-term Debt, Excluding Current MaturitiesUSD $51.86B; Long-term Line of CreditUSD $0.00.
2026-03-31: Commercial PaperUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Line of CreditUSD (m).
2026-03-31: Commercial PaperUSD (m); Long-term Debt, Current MaturitiesUSD $5.44B; Long-term Debt, Excluding Current MaturitiesUSD $51.89B; Long-term Line of CreditUSD $0.00.
2025-12-31: Commercial PaperUSD (m); Long-term Debt, Current MaturitiesUSD $4.60B; Long-term Debt, Excluding Current MaturitiesUSD $50.01B; Long-term Line of CreditUSD $0.00.

Amgen Inc. Debt Components

Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.

Period end	Commercial Paper USD	Long-term Debt, Current Maturities USD	Long-term Debt, Excluding Current Maturities USD	Long-term Line of Credit USD	Long-term Debt USD	Long-Term Debt, Maturity, Year One USD	Long-Term Debt, Maturity, Year Two USD	Long-Term Debt, Maturity, Year Three USD	Long-Term Debt, Maturity, Year Four USD	Long-Term Debt, Maturity, Year Five USD	Long-Term Debt, Maturity, after Year Five USD	Line of Credit Facility, Commitment Fee Percentage pure	Debt Instrument, Face Amount USD	Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD	Notes Payable, Current USD	Debt, Current USD	Short-term Debt, Weighted Average Interest Rate, at Point in Time pure	Line of Credit Facility, Periodic Payment, Principal USD	Debt Instrument, Redemption Price, Percentage pure	Notes Payable, Fair Value Disclosure USD
2026-06-30	(m)	$5.45B	$51.86B	$0.00	$57.30B	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$1.32B	(m)	(m)	(m)	(m)	(m)	(m)
2026-03-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$4.00B	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2026-03-31	(m)	$5.44B	$51.89B	$0.00	$57.32B	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$1.33B	(m)	(m)	(m)	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
GILEAD SCIENCES, INC. (GILD)	United States	$185.522B	-48.37
Moderna, Inc. (MRNA)	United States	$77.819B	-8.86
Revolution Medicines, Inc. (RVMD)	United States	$42.805B	-22.69
BIOGEN INC. (BIIB)	United States	$33.427B	19.60
EXELIXIS, INC. (EXEL)	United States	$14.358B	16.15
NEUROCRINE BIOSCIENCES INC (NBIX)	United States	$14.131B	24.25
HALOZYME THERAPEUTICS, INC. (HALO)	United States	$13.083B	21.59
Twist Bioscience Corp (TWST)	United States	$11.540B	-47.21
BIO-TECHNE Corp (TECH)	United States	$11.379B	74.68
REPLIGEN CORP (RGEN)	United States	$10.755B	185.31